Since C1INH is also an acute phase reactant, it is apt to be present at higher concentrations in patients with AMI, stroke or thromboembolism, so that supplemental C1INH is less likely to be needed, especially at the lower HisproUK doses needed with the synergistic combination. Here, SERPING1 is linked to stroke disorder.